{"id":"da-5212-r","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DA-5212-R acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A receptor agonist, helping to restore neurotransmitter balance in the brain. This dual mechanism is designed to improve cognitive function and reduce neuropsychiatric symptoms associated with neurodegenerative diseases and cognitive disorders.","oneSentence":"DA-5212-R is a small molecule that modulates dopamine and serotonin pathways to treat cognitive and neuropsychiatric symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:29.131Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions"},{"name":"Neuropsychiatric symptoms in cognitive disorders"}]},"trialDetails":[{"nctId":"NCT05842408","phase":"PHASE3","title":"Clinical Trial of DA-5212 in Patients with Functional Dyspepsia","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-06-06","conditions":"Functional Dyspepsia","enrollment":384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DA-5212-R","genericName":"DA-5212-R","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-5212-R is a small molecule that modulates dopamine and serotonin pathways to treat cognitive and neuropsychiatric symptoms. Used for Cognitive impairment associated with Alzheimer's disease or other neurodegenerative conditions, Neuropsychiatric symptoms in cognitive disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}